Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 377 across all filing types
Latest filing 2020-11-12 Interim / Quarterly Rep…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport jan-sep 2020' (Interim Report Jan-Sep 2020) for Immunovia AB. It contains comprehensive financial statements, including the consolidated income statement, balance sheet, cash flow statement, and key performance indicators for the period. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-12 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January-September 2020' for Immunovia AB. It contains comprehensive financial statements, including consolidated income statements, balance sheets, cash flow statements, and key performance indicators for the specified period. It also includes management commentary, CEO statements, and an auditor's review section. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2020
2020-11-12 English
Immunovia presenterar kompletterande information om IMMray® PanCan-d Verifieringsstudien
Regulatory Filings Classification · 95% confidence The document is a press release dated November 2, 2020, titled "Immunovia presenterar kompletterande information om IMMray® PanCan-d Verifieringsstudien" (Immunovia presents supplementary information on the IMMray® PanCan-d Verification Study). It details the results (accuracy, specificity, sensitivity) of a verification study for a diagnostic test and mentions the timeline for the final Validation Study and commercial launch. This type of announcement, providing key updates on clinical/product development milestones and financial/operational news outside of mandatory periodic reports (like 10-K or IR), typically falls under general regulatory announcements or investor relations material. Since it is a press release announcing specific operational/development progress and is not a full financial report (10-K, IR), a management discussion (MDA), or a formal presentation (IP), it best fits the general regulatory announcement category, RNS, as it is explicitly stated to be information the company is obliged to disclose under EU market abuse regulation. Given the content is a detailed update on a product study, it is more specific than a generic RNS, but since there is no specific code for 'Clinical Study Update' or 'Product Development News', RNS serves as the appropriate regulatory filing fallback.
2020-11-02 Swedish
Immunovia Provides Complementary Details on the IMMray[™] PanCan-d Verification Study
Regulatory Filings Classification · 95% confidence The document is titled 'PRESS RELEASE' and provides specific, detailed updates on the outcomes of a 'Verification Study' for a diagnostic test (IMMray™ PanCan-d), including sensitivity, specificity, and NPV figures. It is not a full annual report (10-K), a quarterly report (IR), or a general earnings release (ER) which usually focuses on revenue/profit. It is a specific announcement detailing scientific/clinical progress, which often falls under general investor relations or regulatory disclosure. Since it is a press release detailing specific operational/development progress and is mandated under the EU Market Abuse Regulation, it is best classified as a general Regulatory Filing (RNS) as it doesn't fit the more specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS). Given its nature as a detailed update on a product study, it is not a short announcement of a report (RPA).
2020-11-02 English
Förändring av antal aktier och röster i Immunovia AB (publ)
Share Issue/Capital Change Classification · 95% confidence The document is a press release dated October 30, 2020, announcing a change in the number of shares and votes due to the exercise of warrants as part of an incentive program. This directly relates to a change in the company's capital structure (increase in outstanding shares and share capital). This aligns best with the 'Capital/Financing Update' category (CAP), which covers fundraising, financing activities, or capital structure changes. It is not a general regulatory filing (RNS) because it is highly specific to capital structure, nor is it a share issue/capital change announcement (SHA) which usually implies a formal issuance program, although CAP is the most fitting category for changes resulting from incentive plan exercises affecting the share count.
2020-10-30 Swedish
Change in the Number of Shares and Votes in Immunovia AB (publ)
Share Issue/Capital Change Classification · 98% confidence The document is a press release announcing a specific corporate action: 'Change in the Number of Shares and Votes in Immunovia AB (publ)' due to the 'exercise of warrants' resulting in a 'new share issue'. This directly relates to changes in the company's capital structure and share count. Reviewing the definitions, the 'Share Issue/Capital Change (Code: SHA)' definition fits best: 'Announcement regarding new share issues, stock splits, or other capital changes.' Although 'Transaction in Own Shares (POS)' deals with share issuance/repurchase, SHA is broader and explicitly covers 'new share issues' resulting from warrant exercises, which is the core event here. The document is an announcement, but the subject matter is a direct capital change, making SHA more specific than a general RPA or RNS.
2020-10-30 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.